SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10064	Companies
205717	Keywords
135956	Articles
109065	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 10/24/2024 at 14:00, 1 year 4 months ago

Communiqué de presse : Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI
Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI. Les résultats du Dupixent montrent une réduction significative du prurit et de l'activité de l’urticaire

Traitement Dupixent Phase III Urticaire Chronique Spontanée ACAAI
BRIEF

published on 10/21/2024 at 07:35, 1 year 5 months ago

Sanofi et CD&R unissent leurs forces pour faire croître Opella

Transaction Financière Sanofi CD&R Opella Santé Grand Public
BRIEF

published on 10/21/2024 at 07:35, 1 year 5 months ago

Sanofi and CD&R join forces to grow Opella

Financial Transaction Sanofi CD&R Opella Consumer Health
PRESS RELEASE

published on 10/21/2024 at 07:30, 1 year 5 months ago

Communiqué de presse : Sanofi et CD&R s’allient pour soutenir les ambitions d’Opella dans la santé grand public
Sanofi et CD&R s'allient pour soutenir Opella dans la santé grand public. Opella devient un leader indépendant avec le soutien de Sanofi. CD&R apporte son expérience pour accélérer la croissance

Croissance Sanofi CD&R Opella Santé Grand Public
PRESS RELEASE

published on 10/21/2024 at 07:30, 1 year 5 months ago

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare as Sanofi transfers a 50% stake in Opella. Opella to become a standalone leader backed by Sanofi's strategic support and guidance

Partnership Sanofi CD&R Consumer Healthcare Opella
BRIEF

published on 10/15/2024 at 22:10, 1 year 5 months ago

Sanofi Reports Share and Voting Rights Data for September 2024

Voting Rights Investor Information Sanofi September 2024 Shares Data
BRIEF

published on 10/15/2024 at 22:10, 1 year 5 months ago

Sanofi publie ses données sur les actions et les droits de vote pour septembre 2024

Droit De Vote Sanofi Informations Pour Les Investisseurs Septembre 2024 Partage Des Données
PRESS RELEASE

published on 10/15/2024 at 22:05, 1 year 5 months ago

Sanofi: Information concerning the total number of voting rights and shares - September 2024
Sanofi reports total number of voting rights and shares as of September 30, 2024, in compliance with French commercial and stock market regulations

Voting Rights French Commercial Code Shares Sanofi Stock Market Authority
PRESS RELEASE

published on 10/15/2024 at 22:05, 1 year 5 months ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - SEPTEMBRE 2024
Sanofi communique sur le nombre total de droits de vote et d'actions conformément aux réglementations en vigueur

Autorité Des Marchés Financiers Droits De Vote Actions Règlement Général Sanofi
BRIEF

published on 10/11/2024 at 08:35, 1 year 5 months ago

Sanofi envisage de céder une part majoritaire d'Opella

Participations Santé Sanofi CD&R Opella

Accesswire

Published on 03/23/2026 at 12:20, 10 minutes ago

Guanajuato Silver Adds Veteran Mine Operator to Board of Directors
Published on 03/23/2026 at 12:15, 15 minutes ago

Snipp Interactive Secures US$3 Million Contract, Largest in Company History
Published on 03/23/2026 at 12:00, 30 minutes ago

Churchill Consolidates High-Grade Gold-Antimony Footprint in Central Newfoundland; Enters Option for 100% of Golden Baie
Published on 03/23/2026 at 11:30, 1 hour ago

Trans Canada Gold Provides Update on Non-Brokered Private Placement and Flow-through Private Placement for Drilling at the Harrison Lake District Scale Gold Property Acquisition
Published on 03/23/2026 at 08:00, 4 hours 30 minutes ago

ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 11:44, 45 minutes ago

Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 1 hour ago

EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 1 hour 23 minutes ago

Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 1 hour 24 minutes ago

ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 1 hour 25 minutes ago

BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology

Les Echos

Published on 03/23/2026 at 08:10, 4 hours 20 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE